Compare SPRY & PLSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPRY | PLSE |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 946.0M | 1.2B |
| IPO Year | N/A | 2016 |
| Metric | SPRY | PLSE |
|---|---|---|
| Price | $11.36 | $15.30 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $31.25 | $22.00 |
| AVG Volume (30 Days) | ★ 2.0M | 191.2K |
| Earning Date | 11-10-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $142,772,000.00 | $86,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $124.59 | $1,002.94 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 5459.66 | N/A |
| 52 Week Low | $6.66 | $12.56 |
| 52 Week High | $18.90 | $25.00 |
| Indicator | SPRY | PLSE |
|---|---|---|
| Relative Strength Index (RSI) | 63.41 | 61.80 |
| Support Level | $9.78 | $13.94 |
| Resistance Level | $10.71 | $14.70 |
| Average True Range (ATR) | 0.73 | 0.68 |
| MACD | 0.10 | 0.30 |
| Stochastic Oscillator | 94.33 | 76.83 |
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.